Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-543

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 68001-543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival curve chart displaying overall survival percentage over time in months for two treatment arms labeled A+P+C and A+C. The vertical axis shows overall survival (%) from 0 to 100, while the horizontal axis shows time in months from 0 to 21. The chart includes a table below indicating the number of patients at risk over time for each treatment arm.*

FDA Label Image

Figure2 (Figure2)

A Kaplan-Meier survival curve comparing survival probability over time (months) for two treatment groups: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dashed line). The x-axis represents survival time in months up to 30, and the y-axis shows survival probability from 0 to 1. Patient numbers at risk are included below the graph for both groups at various time points.*

FDA Label Image

Figure3 (Figure3)

A survival probability curve comparing two treatments over 30 months: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line). Survival probability is plotted on the vertical axis, and survival time in months on the horizontal axis. A table below shows the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Figure4 (Figure4)

A survival curve chart comparing survival probability over time (in months) for patients treated with Pemetrexed + Cisplatin (PC) versus Gemcitabine + Cisplatin (GC). The plot shows survival probability on the vertical axis and survival time up to 30 months on the horizontal axis. Patient counts at risk for each treatment group are listed below the timeline.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve comparing survival probability over time (up to 42 months) between patients treated with Pemetrexed and placebo. The graph includes a table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure6 (Figure6)

A survival curve chart comparing survival probability over time in months for patients treated with Pemetrexed versus placebo. The chart includes survival probabilities on the vertical axis and survival time in months on the horizontal axis, with patient risk numbers listed below for both groups.*

FDA Label Image

Figure7 (Figure7)

A Kaplan-Meier survival curve chart showing survival probability over time in months for patients treated with Pemetrexed compared to placebo. The chart includes survival curves labeled for Pemetrexed (solid line) and placebo (dotted line) and a table of patients at risk below the x-axis over the study duration up to 42 months.*

FDA Label Image

Figure8 (Figure8)

A survival curve chart displaying survival probability over time (months) comparing Pemetrexed and Placebo groups. The solid line represents Pemetrexed and the dotted line represents Placebo. Below the graph is a table showing the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure9 (Figure9)

A survival probability Kaplan-Meier curve comparing Pemetrexed plus Cisplatin combination therapy versus Cisplatin alone over time in months. The graph includes a survival probability y-axis, survival time x-axis, and a table listing patients at risk at various time points for each treatment group.*

FDA Label Image

Carton 100mg (Pemetrexed 100mg Carton)

Packaging label for Pemetrexed for Injection, USP 100 mg/vial powder for injection, lyophilized, for intravenous use. The label includes the NDC 68001-543-41 and states the drug is a cytotoxic agent. Manufactured for BluePoint Laboratories, with detailed instructions for reconstitution and storage. The label design features the OncoPoint logo and a barcode.*

FDA Label Image

Carton 500mg (Pemetrexed 500mg Carton)

Label for Pemetrexed for Injection, USP 500 mg/vial powder for injection, lyophilized, for intravenous use. The label includes usage caution as a cytotoxic agent and storage instructions. Manufactured by Gland Pharma Limited, India, for BluePoint Laboratories. NDC 68001-544-41. Packaging indicates a single-dose vial with detailed reconstitution and administration guidelines.*

FDA Label Image

Label 100mg (Pemetrexed Vial 100mg)

Label for Pemetrexed injection, lyophilized powder for solution, 100 mg/4 mL strength. The label shows Pemetrexed disodium as the active ingredient for intravenous use. It indicates single-dose vial packaging by BluePoint Laboratories, with storage instructions and a caution noting it is a cytotoxic agent.*

FDA Label Image

Label 500mg (Pemetrexed Vial 500mg)

Label for Pemetrexed for Injection, USP powder for solution, 500 mg per vial. It is indicated for intravenous use only and labeled as a cytotoxic agent. The label states it is a single-dose vial manufactured by Gland Pharma Limited, India, for BluePoint Laboratories. Storage instructions and cautionary information about pH adjustment agents are included.*

FDA Label Image

Structure (Structure)

Chemical structure of pemetrexed disodium showing its molecular arrangement including rings and functional groups as part of the drug's active ingredient representation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.